DeepMed Research

Paricalcitol

Generic Name: Paricalcitol

Brand Names: Zemplar

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₄O_₃

CAS Number: 131918-61-1

Unique Ingredient Identifier: 6702D36OG5

Background: Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Indication: For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Associated Conditions: Secondary Hyperparathyroidism (SHPT)

Clinical Trials

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism
Dialysis

Interventions: Drug: Paricalcitol capsules
Drug: Paricalcitol injection

First Posted Date: 2007-10-02

Last Posted Date: 2011-10-25

Lead Sponsor: Abbott

Target Recruit Count: 147

Registration Number: NCT00537979

Locations: 🇲🇽
Site Ref # / Investigator 19391, Jojutla Morelos, Mexico
🇲🇽
Site Ref # / Investigator 19389, Mexico City, Mexico
🇲🇽
Site Ref # / Investigator 19396, Mexico D.F., Mexico

and more 9 locations

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

Phase 3

Completed

Conditions: Chronic Kidney Disease
Left Ventricular Hypertrophy

Interventions: Drug: placebo
Drug: paricalcitol

First Posted Date: 2007-07-06

Last Posted Date: 2013-03-12

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 227

Registration Number: NCT00497146

Locations: 🇷🇺
Site Reference ID/Investigator# 7251, Moscow, Russian Federation
🇨🇳
Site Reference ID/Investigator# 8228, Taipei, Taiwan
🇷🇴
Site Reference ID/Investigator# 8881, Bucharest, Romania

and more 68 locations

Treatment of Secondary Hyperparathyroidism in the Uremic Patient

Not Applicable

Terminated

Conditions: Secondary Hyperparathyroidism
Chronic Kidney Disease
Vitamin D Deficiency

Interventions: Drug: paricalcitol
Drug: alfacalcidol

First Posted Date: 2007-05-04

Last Posted Date: 2011-04-04

Lead Sponsor: Zealand University Hospital

Target Recruit Count: 86

Registration Number: NCT00469599

Locations: 🇩🇰
Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Århus University Hospital Skejby, Aarhus, Denmark
🇩🇰
Hospital of Southwest Denmark Esbjerg, Esbjerg, Denmark

and more 5 locations

A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease

Not Applicable

Withdrawn

Conditions: Proteinuric Renal Disease

First Posted Date: 2007-05-04

Last Posted Date: 2015-12-28

Lead Sponsor: Winthrop University Hospital

Registration Number: NCT00469625

Locations: 🇺🇸
Winthrop Univ. Hospital, Mineola, New York, United States

A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism

First Posted Date: 2007-04-19

Last Posted Date: 2015-05-05

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 36

Registration Number: NCT00463021

A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism

First Posted Date: 2007-03-30

Last Posted Date: 2015-05-05

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 12

Registration Number: NCT00454350

Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation

Not Applicable

Completed

Conditions: Chronic Kidney Disease
Endothelial Dysfunction
Inflammation
Hypertension

Interventions: Drug: Placebo
Drug: paricalcitol

First Posted Date: 2007-01-29

Last Posted Date: 2009-06-03

Lead Sponsor: Indiana University School of Medicine

Target Recruit Count: 24

Registration Number: NCT00428246

Locations: 🇺🇸
Richard A. Rodebush VA Medical Center, Indianapolis, Indiana, United States

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

Phase 2

Completed

Conditions: Diabetic Nephropathy
Chronic Kidney Disease

Interventions: Drug: Zemplar (paricalcitol ) capsules
Drug: Zemplar (paricalcitol) capsules
Drug: Placebo

First Posted Date: 2007-01-12

Last Posted Date: 2012-01-20

Lead Sponsor: Abbott

Target Recruit Count: 281

Registration Number: NCT00421733

Locations: 🇺🇸
Site Reference ID/Investigator# 856, Dallas, Texas, United States
🇺🇸
Site Reference ID/Investigator# 7214, Omaha, Nebraska, United States
🇺🇸
Site Reference ID/Investigator# 6626, Winston-Salem, North Carolina, United States

and more 69 locations

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

Phase 3

Completed

Conditions: Hypophosphatemia, Familial
Hyperparathyroidism

Interventions: Drug: Paricalcitol
Other: Placebo

First Posted Date: 2007-01-01

Last Posted Date: 2020-03-17

Lead Sponsor: Yale University

Target Recruit Count: 33

Registration Number: NCT00417612

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States

Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism

Phase 4

Completed

Conditions: Secondary Hyperparathyroidism

First Posted Date: 2006-03-28

Last Posted Date: 2006-03-28

Lead Sponsor: Papageorgiou General Hospital

Registration Number: NCT00307840

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy